Clinical trials · Cincinnati, OH
Small Cell Lung Cancer clinical trials in Cincinnati
We’re tracking 72 recruiting small cell lung cancer studies with a site in or near Cincinnati — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Cincinnati
- NCT03866382RecruitingPhase 2
Immunotherapy plus a targeted drug for rare genitourinary tumors
This Phase 2 study tests whether nivolumab and ipilimumab (immunotherapy drugs) plus cabozantinib (a targeted anti-cancer drug) can shrink or control rare cancers of the urinary/reproductive system that have spread. It may help by boosting the immune system and blocking cancer growth signals at the same time.
Cincinnati, OhioAges 18 years+ - NCT06632327RecruitingPhase 3
Comparing treatment timing for stage II-IIIB lung cancer
This trial is for people with a certain type of lung cancer (non-small cell lung cancer) that can be surgically removed. It tests whether it is better to receive treatment before or after surgery to remove the cancer.
Cincinnati, OhioAges 18 years+ - NCT05624996RecruitingPhase 3
Targeted high-dose radiation added to standard lung cancer treatment
This trial tests whether adding high-dose, targeted radiation to the usual treatment helps people with locally advanced, non-operable lung cancer live longer or better control the cancer. It may help shrink tumors in the chest and improve outcomes when surgery can’t be done.
Cincinnati, OhioAges 18 years+ - NCT04614103RecruitingPhase 2
Immune cell therapy for advanced lung cancer after chemotherapy
This trial studies LN-145, a treatment made from your own immune cells, for metastatic (stage IV) non-small-cell lung cancer. It may help shrink tumors after your cancer has progressed despite standard first-line chemotherapy and immunotherapy.
Cincinnati, OhioAges 18–70 - NCT07361497RecruitingPhase 3
New Drug vs Standard Drug After Chemoradiation for Stage 3 Lung Cancer
This study tests a new drug, pumitamig, against an older drug, durvalumab, for people with stage 3 non-small cell lung cancer that cannot be removed by surgery and has not progressed after chemotherapy and radiation. The goal is to see which drug works better to keep the cancer from growing.
Cincinnati, OhioAges 18 years+ - NCT07361510RecruitingPhase 3
Pumitamig vs Keytruda for advanced lung cancer with high PD-L1
This trial compares an experimental drug called Pumitamig with the approved immunotherapy drug Pembrolizumab (Keytruda) as the first treatment for advanced lung cancer that has high PD-L1 levels. The goal is to see which drug works better and has fewer side effects.
Cincinnati, OhioAges 18 years+ - NCT05671510RecruitingPhase 3
Trial for metastatic lung cancer after PD-1 or PD-L1 treatment failure
This trial compares ONC-392 versus docetaxel (a standard chemotherapy) in metastatic squamous non-small cell lung cancer that has grown again after PD-1/PD-L1 immunotherapy. It’s testing whether ONC-392 can control the cancer better or more safely after prior treatment.
Cincinnati, OhioAges 18 years+ - NCT05642572RecruitingPhase 2
Test drug combinations for EGFR- and MET-changed lung cancer
This Phase 2 trial tests combinations of targeted medicines to treat advanced non-small cell lung cancer (NSCLC) that has changes in both EGFR and MET genes. It is for people whose cancer continued to grow even after treatment with osimertinib, the most recent therapy.
Cincinnati, OhioAges 18 years+ - NCT06773910RecruitingPhase 2
New drug combo vs standard care for limited-stage small cell lung cancer
This trial tests a new combination of drugs (atigotatug and nivolumab) against the standard drug durvalumab for people with limited-stage small cell lung cancer who have completed chemotherapy and radiation without the cancer getting worse. The goal is to see if the new combination works better at keeping the cancer from coming back.
Cincinnati, OhioAges 18 years+ - NCT06303505RecruitingPhase 1/Phase 2
Study of TUB-040 for ovarian and lung cancer
This study tests a new drug called TUB-040 that targets a protein (NaPi2b) found on some ovarian and lung cancer cells. It is for people whose cancer has stopped responding to standard treatments and who have not had certain lung problems in the past.
Cincinnati, OhioAges 18 years+ - NCT06767514RecruitingPhase 3
Ivonescimab for first-line treatment of advanced NSCLC with high PD-L1
This trial tests a new drug called Ivonescimab as the first treatment for people with advanced (stage IV) non-small cell lung cancer whose tumors have high levels of PD-L1 (a protein that helps cancer hide from the immune system). The goal is to see if it can help shrink or control the cancer.
Cincinnati, OhioAges 18 years+ - NCT06623422RecruitingPhase 3
Vaccine plus Keytruda for lung cancer after surgery
This trial tests combining a cancer vaccine (V940) with the immunotherapy drug pembrolizumab (Keytruda) for people with non-small cell lung cancer that was treated with chemo and Keytruda before surgery but wasn't completely removed. The goal is to see if adding the vaccine helps prevent the cancer from coming back.
Cincinnati, OhioAges 18 years+ - NCT06073431Recruiting
Study on weight loss types in advanced cancer
This study looks at different types of weight loss (cachexia) in people with advanced lung, pancreatic, or colorectal cancer. Researchers want to find patterns to better understand and treat it. You can join even if you haven't lost weight yet.
Cincinnati, OhioAges 18 years+ - NCT06667076RecruitingPhase 2
Amivantamab combinations for advanced EGFR-mutant lung cancer
This trial tests two treatment combinations for people with a specific type of advanced lung cancer that has an EGFR mutation. One group gets amivantamab plus lazertinib, and the other gets amivantamab plus chemotherapy. The goal is to see which combo works better.
Cincinnati, OhioAges 18 years+ - NCT06692738RecruitingPhase 3
Is a new immunotherapy better than Keytruda for squamous lung cancer?
This trial tests a new drug called Rilvegostomig against the standard drug pembrolizumab (Keytruda), both combined with chemotherapy, as a first treatment for advanced squamous non-small cell lung cancer. It aims to see which combination works better.
Cincinnati, OhioAges 18 years+ - NCT05257551Recruiting
Small cell lung cancer data study using tumor and blood samples
This observational study collects information and lab samples from people with extensive-stage small cell lung cancer. It may help researchers understand how patients respond and improve future care, but it usually does not add new treatment for you.
Cincinnati, OhioAges 18 years+ - NCT05703971RecruitingPhase 1/Phase 2
Maintenance treatment with a gene therapy plus atezolizumab
This Phase 1/2 trial tests whether a gene therapy called Reqorsa given with atezolizumab can help people with extensive-stage small cell lung cancer (ES-SCLC) stay controlled after their first chemo. It may help by boosting the immune system to keep the cancer from growing again.
Cincinnati, OhioAges 18 years+ - NCT07207395RecruitingPhase 2
Study of JBI-802 with or without pembrolizumab for STK11-mutated lung cancer
This trial tests a new oral drug, JBI-802, alone or with pembrolizumab, for people with advanced non-small cell lung cancer that has a specific change in the STK11 gene. The goal is to see if this treatment can help shrink tumors or slow their growth.
Cincinnati, OhioAges 18 years+ - NCT05059444Recruiting
Blood test study to watch for cancer coming back
This study looks at whether blood tests can detect signs that cancer may return after curative-intent treatment. You would have blood drawn around your usual follow-up visits for up to 5 years, and your de-identified health data would be shared with study investigators.
Cincinnati, OhioAges 18 years+ - NCT07225036Recruiting
Low-dose liver radiation to boost immunotherapy
This trial tests whether adding a low dose of radiation to the liver can make standard immunotherapy work better for people with non-small cell lung cancer or melanoma that has spread to the liver.
Cincinnati, OhioAges 18 years+ - NCT06236438RecruitingPhase 2/Phase 3
Livmoniplimab plus budigalimab and chemo for untreated lung cancer
This trial tests a new combination of two immune system drugs (livmoniplimab and budigalimab) plus standard chemotherapy compared to the current standard treatment (pembrolizumab plus chemo) for people with advanced non-small cell lung cancer that has not been treated yet. The goal is to see if the new combination works better at controlling the cancer.
Cincinnati, OhioAges 18 years+ - NCT06765109RecruitingPhase 3
Testing neladalkib for untreated ALK-positive lung cancer
This study tests a new pill called neladalkib to see if it works better than the current standard treatment (alectinib) for people with ALK-positive lung cancer who have not yet received any cancer therapy for advanced disease. It may be a good option if you have ALK-positive NSCLC and have not been treated before.
Cincinnati, OhioAges 18 years+ - NCT06040541RecruitingPhase 1
Study of RMC-9805 for KRAS G12D solid tumors
This trial tests an experimental pill (RMC-9805) for people with solid tumors that have a specific KRAS G12D mutation. It's for those who have already tried other treatments and need new options.
Cincinnati, OhioAges 18 years+ - NCT07005128RecruitingPhase 3
New Drug Combo for First-Line Extensive Small Cell Lung Cancer
This trial tests adding a new immunotherapy drug (tarlatamab) to the standard first-line chemo-immunotherapy for extensive-stage small cell lung cancer. It aims to see if the combination works better than the usual treatment alone.
Cincinnati, OhioAges 18–99
Hear when a new Small Cell Lung Cancer trial opens near Cincinnati, OH
We’ll email you when one opens near Cincinnati, OH — at most once a week, no account needed, unsubscribe anytime.
Small Cell Lung Cancer trials in other cities
Where these studies are running near Cincinnati
Institutions with a site for the recruiting small cell lung cancer studies listed above.
- Oncology Hematology Care · 7 studies
- University of Cincinnati Cancer Center-UC Medical Center · 7 studies
- Atrium Medical Center · 5 studies
- Miami Valley Hospital South · 5 studies
- Kettering Medical Center · 4 studies
- The Christ Hospital · 4 studies
- TriHealth Cancer Institute · 4 studies
- Bethesda North Hospital · 3 studies
What taking part in a small cell lung cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting small cell lung cancer studies in Ohio.
Common questions
- Are there small cell lung cancer clinical trials near Cincinnati?
- Yes. We're currently tracking 72 recruiting small cell lung cancer studies with a site near Cincinnati, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a small cell lung cancer study near Cincinnati?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Cincinnati to take part?
- Not necessarily. These studies have a site near Cincinnati, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a small cell lung cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New small cell lung cancer studies open near Cincinnati regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.